Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 21% ± 3% | |
natural killer cell | 5 studies | 23% ± 7% | |
B cell | 4 studies | 36% ± 12% | |
naive B cell | 4 studies | 20% ± 3% | |
CD8-positive, alpha-beta T cell | 4 studies | 27% ± 6% | |
epithelial cell | 4 studies | 32% ± 12% | |
ciliated cell | 4 studies | 19% ± 4% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 23% ± 6% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 24% ± 6% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 29% ± 7% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 29% ± 5% | |
CD4-positive, alpha-beta T cell | 3 studies | 35% ± 10% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 31% ± 10% | |
mature NK T cell | 3 studies | 20% ± 3% | |
CD4-positive helper T cell | 3 studies | 22% ± 5% | |
gamma-delta T cell | 3 studies | 25% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 4 studies | 33% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 2596.92 | 258 / 258 | 100% | 31.44 | 230 / 230 |
bladder | 100% | 1868.76 | 21 / 21 | 100% | 24.26 | 504 / 504 |
breast | 100% | 2056.02 | 459 / 459 | 100% | 22.18 | 1118 / 1118 |
esophagus | 100% | 1855.94 | 1445 / 1445 | 100% | 25.72 | 183 / 183 |
intestine | 100% | 1898.22 | 966 / 966 | 100% | 21.34 | 527 / 527 |
kidney | 100% | 1555.82 | 89 / 89 | 100% | 21.03 | 901 / 901 |
ovary | 100% | 1990.62 | 180 / 180 | 100% | 18.12 | 430 / 430 |
prostate | 100% | 2065.98 | 245 / 245 | 100% | 24.40 | 502 / 502 |
skin | 100% | 2260.70 | 1809 / 1809 | 100% | 25.02 | 472 / 472 |
stomach | 100% | 1510.24 | 359 / 359 | 100% | 20.69 | 286 / 286 |
uterus | 100% | 2038.20 | 170 / 170 | 100% | 23.45 | 459 / 459 |
brain | 100% | 3217.19 | 2639 / 2642 | 100% | 32.69 | 705 / 705 |
thymus | 100% | 2083.73 | 652 / 653 | 100% | 28.17 | 605 / 605 |
lung | 100% | 1730.95 | 577 / 578 | 100% | 21.58 | 1155 / 1155 |
pancreas | 100% | 1402.02 | 327 / 328 | 100% | 19.99 | 178 / 178 |
liver | 100% | 1326.49 | 226 / 226 | 99% | 12.22 | 403 / 406 |
adipose | 100% | 2106.33 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 24.44 | 29 / 29 |
spleen | 100% | 2403.24 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 16.71 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.92 | 1 / 1 |
blood vessel | 100% | 1774.84 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1567.02 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 1169.29 | 852 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 18.80 | 79 / 80 |
peripheral blood | 58% | 722.28 | 537 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006396 | Biological process | RNA processing |
GO_0034475 | Biological process | U4 snRNA 3'-end processing |
GO_0071051 | Biological process | poly(A)-dependent snoRNA 3'-end processing |
GO_0006401 | Biological process | RNA catabolic process |
GO_0045006 | Biological process | DNA deamination |
GO_0016075 | Biological process | rRNA catabolic process |
GO_0071028 | Biological process | nuclear mRNA surveillance |
GO_0045190 | Biological process | isotype switching |
GO_0000956 | Biological process | nuclear-transcribed mRNA catabolic process |
GO_0006364 | Biological process | rRNA processing |
GO_0045830 | Biological process | positive regulation of isotype switching |
GO_0005730 | Cellular component | nucleolus |
GO_0000178 | Cellular component | exosome (RNase complex) |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000177 | Cellular component | cytoplasmic exosome (RNase complex) |
GO_0101019 | Cellular component | nucleolar exosome (RNase complex) |
GO_0005829 | Cellular component | cytosol |
GO_0000176 | Cellular component | nuclear exosome (RNase complex) |
GO_0005634 | Cellular component | nucleus |
GO_0004532 | Molecular function | RNA exonuclease activity |
GO_0003723 | Molecular function | RNA binding |
Gene name | EXOSC6 |
Protein name | Exosome complex component MTR3 (Exosome component 6) (mRNA transport regulator 3 homolog) (hMtr3) (p11) |
Synonyms | MTR3 |
Description | FUNCTION: Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes. . |
Accessions | ENST00000435634.3 Q5RKV6 |